N A Kennedy
Overview
Explore the profile of N A Kennedy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalla R, Adams A, Bergemalm D, Vatn S, Kennedy N, Ricanek P, et al.
J Crohns Colitis
. 2020 Nov;
15(5):699-708.
PMID: 33201212
Background: Success in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic...
2.
Hunt W, Wheeler J, Kennedy N, Burden T, McGrath E
Clin Exp Dermatol
. 2020 Sep;
46(1):216-218.
PMID: 32931629
No abstract available.
3.
Kalla R, Adams A, Ventham N, Kennedy N, White R, Clarke C, et al.
J Crohns Colitis
. 2020 Jun;
14(12):1724-1733.
PMID: 32598439
Background: MicroRNAs [miRNAs] are cell-specific small non-coding RNAs that can regulate gene expression and have been implicated in inflammatory bowel disease [IBD] pathogenesis. Here we define the cell-specific miRNA profiles...
4.
Jones G, Fasci-Spurio F, Kennedy N, Plevris N, Jenkinson P, Lyons M, et al.
J Crohns Colitis
. 2018 Nov;
13(4):442-450.
PMID: 30452618
Background And Aims: Magnetic resonance enterography [MRE] is the gold standard for assessing ileal inflammation in Crohn's disease [CD]. The aim of the present study was to correlate faecal calprotectin...
5.
Walker G, Moore L, Heerasing N, Hendy P, Perry M, McDonald T, et al.
Aliment Pharmacol Ther
. 2018 Mar;
47(8):1103-1116.
PMID: 29508423
Background: Primary care faecal calprotectin testing distinguishes inflammatory bowel disease (IBD) from functional gut disorder in young patients presenting with abdominal symptoms; however, previous evaluations have excluded patients with alarm...
6.
Kennedy N, Goodhand J, Rampton D
Aliment Pharmacol Ther
. 2017 Jun;
46(2):194-195.
PMID: 28621066
No abstract available.
7.
Ho G, Aird R, Liu B, Boyapati R, Kennedy N, Dorward D, et al.
Mucosal Immunol
. 2017 Apr;
11(1):120-130.
PMID: 28401939
The multidrug resistance-1 (MDR1) gene encodes an ATP-dependent efflux transporter that is highly expressed in the colon. In mice, loss of MDR1 function results in colitis with similarities to human...
8.
Heerasing N, Thompson B, Hendy P, Heap G, Walker G, Bethune R, et al.
Aliment Pharmacol Ther
. 2017 Jan;
45(5):660-669.
PMID: 28105752
Background: Few studies have reported the systematic use of exclusive enteral nutrition in the perioperative setting. Aim: To test the hypothesis that exclusive enteral nutrition provides a safe and effective...
9.
Ventham N, Kennedy N, Adams A, Kalla R, Heath S, OLeary K, et al.
Nat Commun
. 2016 Nov;
7:13507.
PMID: 27886173
Epigenetic alterations may provide important insights into gene-environment interaction in inflammatory bowel disease (IBD). Here we observe epigenome-wide DNA methylation differences in 240 newly-diagnosed IBD cases and 190 controls. These...
10.
Kennedy N, Warner B, Johnston E, Flanders L, Hendy P, Ding N, et al.
Aliment Pharmacol Ther
. 2016 Feb;
43(8):910-923.
PMID: 26892328
Background: Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There...